An embodiment provides a method for treating a body fluid of a patient with Alzheimer's Disease, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an Alzheimer's targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a tag sensitive to an illumination; removing the antibody-TA complex from the body fluid using an illumination source; and returning the body fluid to the patient. Other aspects are described and claimed.

Disclosed herein are synthetic hydrogels suitable for delivering antimicrobial proteins, optionally in combination with bone regenerating agents to injured tissues. The hydrogels can include lysostaphin and one or more bone morphogenic proteins. The hydrogels are composed of a network of crosslinked hydrophilic polymers and adhesion peptides.

A medical device is disclosed. The medical device includes an RFID reader for receiving information from at least one RFID transponder. The medical device also includes a memory for storing a database and at least one processor for processing information. Also, a remote controller for a medical device is disclosed. The remote controller includes an information receiver for receiving information related to food. The infusion device also includes a memory for storing a database and at least one processor for processing information. A method for use in a medical device is also disclosed. The method includes receiving information from an RFID transponder related to food. Also, the processing the information by comparing the information to a database is included in the method. The method also includes determining the acceptability of the food and providing information related to acceptability to the user.

The invention relates to the treatment of an individual suffering from a cytokine storm syndrome. It relates to methods for the treatment of such an individual and to systems and devices for use in such treatment.

A method and system for treating Alzheimer's disease wherein blood, spinal fluid or brain cavity fluid is circulated into and outside of the body by means of blood pumps or other external circulatory systems. While passing through the pumping system, the amyloid plaques and Tao tangles are filtered from the fluids and returned to the body lowering the protein levels, and in the process, reduce symptoms. In one embodiment a patient's blood is filtered using a pump to circulate the blood from the patient to the collection vessel where an electrical current will cause anything that has a positive charge to be attracted to a cathode plate suspended in the collection vessel for later disposal. In an alternate embodiment a patient's brain and/or spinal fluid a pump operates to circulate a flushing fluid. The pump will circulate the solution from the collection vessel to the patient.

The present invention provides a particulate delivery device with an automatic activation mechanism that pierces or cuts a composition capsule when a cap is removed. The cap cannot be replaced once the device is activated for use. The device allows for gas flow through the device from a gas inlet to a gas outlet through a composition receptacle and dispersion chamber to deliver particulate to the airway of a subject.

Core annular flow is used to enable the subcutaneous delivery of a viscous fluid such as a protein therapeutic formulation. The high-viscosity fluid is surrounded by a low-viscosity fluid, and the low-viscosity fluid lubricates the passage of the high-viscosity fluid. This allows the use of protein formulations that have a higher concentration and a higher viscosity at comparatively reduced injection forces and reduced injection times. Several different embodiments of injection devices that provide core annular flow are described herein.

A dialysis device (100) comprises: a dialyzer for exchange of substances between a blood flow and a dialysate flow in a dialysis area (106) of the dialyzer, wherein the dialyzer comprises a dialyzer membrane (110) for passing toxins in the blood flow to the dialysate flow through pores (112) of the dialyzer membrane (110); and a capacitively coupled generator (120) for generating electromagnetic fields in the dialysis area (106) for loosening electrostatic bonds between toxins and proteins in the blood flow, wherein the generator (120) is capacitively coupled to the blood flow and to the dialysate flow on opposite sides of the dialyzer membrane, and wherein the dialysate membrane (110) is formed of a material having lower conductance than blood and dialysate such that a large electromagnetic field strength is provided across the pores (112) of the dialyzer membrane (110).

The present invention relates to antigen binding sites, compositions and uses thereof in the treatment of conditions associated with pathogenic proteins. In one example the condition is Alzheimer's disease.

A cryo formulation-based microneedle device for ocular delivery of bioactive therapeutic agents. The microneedle device includes: one or more microneedle patches each including an array of miniaturized needles, wherein each miniaturized needle defining a base end and a tip; and a substrate to which the base end of the array of miniaturized needles is attached or integrated thereto; wherein the microneedle patch is in a cryo status; wherein each of the one or more microneedle patch is adapted to be applied on cornea of an eye, in which the miniaturized needles penetrates into the eye; and wherein the miniaturized needles is further arranged to melt so as to release one or more bioactive therapeutic agents into the eye to achieve a targeted therapeutic effect.